» Articles » PMID: 12479825

Cell Membrane Modification for Rapid Display of Proteins As a Novel Means of Immunomodulation: FasL-decorated Cells Prevent Islet Graft Rejection

Overview
Journal Immunity
Publisher Cell Press
Date 2002 Dec 14
PMID 12479825
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Long-term display of exogenous proteins on the cell surface may have important research and therapeutic implications. We report a novel method for the cell-surface display of proteins that involves generation of a chimeric protein with core streptavidin, biotinylation of cells, and "decoration" with the protein. A chimeric protein with the extracellular portions of FasL (SA-FasL) was efficiently displayed on the cell surface within 2 hr without detectable cellular toxicity. Biotin and SA-FasL persisted on the cell surface for weeks in vitro and in vivo. Immunomodulation with SA-FasL-decorated splenocytes effectively blocked alloreactive responses in naive and presensitized rodents and prevented the rejection of allogeneic pancreatic islets. This approach may serve as an alternative to gene transfer-based expression with broad research and therapeutic applications.

Citing Articles

Engineering Pancreatic Islets to Transiently Codisplay on Their Surface Thrombomodulin and CD47 Immunomodulatory Proteins as a Means of Mitigating Instant Blood-Mediated Inflammatory Reaction following Intraportal Transplantation.

Turan A, Tarique M, Zhang L, Kazmi S, Ulker V, Tedla M J Immunol. 2024; 212(12):1971-1980.

PMID: 38709159 PMC: 11160431. DOI: 10.4049/jimmunol.2300743.


Engineering pancreatic islets with a novel form of thrombomodulin protein to overcome early graft loss triggered by instant blood-mediated inflammatory reaction.

Turan A, Zhang L, Tarique M, Ulker V, Arguc F, Badal D Am J Transplant. 2023; 23(5):619-628.

PMID: 36863480 PMC: 10318623. DOI: 10.1016/j.ajt.2023.02.021.


Engineering donor lymphocytes with Fas ligand protein effectively prevents acute graft-versus-host disease.

Shrestha P, Turan A, Batra L, Gulen A, Sun Z, Tan H Blood Adv. 2023; 7(10):2181-2195.

PMID: 36780582 PMC: 10196989. DOI: 10.1182/bloodadvances.2022008495.


FasL microgels induce immune acceptance of islet allografts in nonhuman primates.

Lei J, Coronel M, Yolcu E, Deng H, Grimany-Nuno O, Hunckler M Sci Adv. 2022; 8(19):eabm9881.

PMID: 35559682 PMC: 9106299. DOI: 10.1126/sciadv.abm9881.


Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases.

Risso V, Lafont E, Le Gallo M Cell Death Dis. 2022; 13(3):248.

PMID: 35301281 PMC: 8931059. DOI: 10.1038/s41419-022-04688-x.